{"id":13028,"date":"2023-07-24T23:07:01","date_gmt":"2023-07-24T21:07:01","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&#038;p=13028"},"modified":"2026-03-26T11:16:39","modified_gmt":"2026-03-26T10:16:39","slug":"glp1-gip-tirzepatide-2-5-mg","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/shop-product\/glp1-gip-tirzepatide-2-5-mg\/","title":{"rendered":"Tirzepatide 2.5 mg vial (GLP1+GIP)"},"content":{"rendered":"<div data-elementor-type=\"product-post\" data-elementor-id=\"13028\" class=\"elementor elementor-13028\" data-elementor-post-type=\"product\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-53f3d7d elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"53f3d7d\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e6006d1\" data-id=\"e6006d1\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-64391bc elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"64391bc\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2 data-start=\"512\" data-end=\"564\">Tirzepatide 2.5 mg vial - characteristics<\/h2><p data-start=\"566\" data-end=\"843\"><strong data-start=\"566\" data-end=\"588\">Tirzepatide 2.5 mg<\/strong> is a synthetic peptide that is a dual agonist of GIP and GLP-1 receptors. This compound has been extensively studied in the scientific literature in the context of incretin signaling, regulation of glucose metabolism and mechanisms of energy balance control.<\/p><hr data-start=\"908\" data-end=\"911\" \/><h2 data-start=\"913\" data-end=\"982\">What is tirzepatide 2.5 mg and what is its mechanism of action?<\/h2><p data-start=\"984\" data-end=\"1093\">Tirzepatide is a single molecule designed to simultaneously activate two incretin receptors:<\/p><ul data-start=\"1095\" data-end=\"1428\"><li data-start=\"1095\" data-end=\"1271\"><p data-start=\"1097\" data-end=\"1271\"><strong data-start=\"1097\" data-end=\"1150\">GLP-1 receptor (glucagon-like peptide-1 receptor)<\/strong> - associated with glucose-dependent insulin secretion, modulation of glucagon secretion and effects on satiety signaling.<\/p><\/li><li data-start=\"1272\" data-end=\"1428\"><p data-start=\"1274\" data-end=\"1428\"><strong data-start=\"1274\" data-end=\"1346\">GIP receptor (glucose-dependent insulinotropic polypeptide receptor)<\/strong> - involved in the regulation of insulin response and metabolic processes.<\/p><\/li><\/ul><p data-start=\"1430\" data-end=\"1726\">Dual activation of these pathways distinguishes tirzepatide from classical GLP-1 agonists. This mechanism has been described in detail in clinical trials of the SURPASS program and SURMOUNT, where the molecule's effects on glycemic parameters and body weight were analyzed under controlled study conditions.<\/p><hr data-start=\"1728\" data-end=\"1731\" \/><h2 data-start=\"1733\" data-end=\"1777\">Tirzepatide 2.5 mg in clinical models<\/h2><p data-start=\"1779\" data-end=\"1879\">Published clinical studies have shown that tirzepatide as a class of incretin molecules:<\/p><ul data-start=\"1881\" data-end=\"2079\"><li data-start=\"1881\" data-end=\"1942\"><p data-start=\"1883\" data-end=\"1942\">significantly affects parameters of glucose metabolism (HbA1c),<\/p><\/li><li data-start=\"1943\" data-end=\"2013\"><p data-start=\"1945\" data-end=\"2013\">Affects mechanisms regulating appetite and energy balance,<\/p><\/li><li data-start=\"2014\" data-end=\"2079\"><p data-start=\"2016\" data-end=\"2079\">demonstrates the dose dependence of the effect in escalation protocols.<\/p><\/li><\/ul><p data-start=\"2081\" data-end=\"2259\">The 2.5 mg dose in the clinical regimens acted as the starting dose in the escalation models, allowing assessment of the body's tolerance and adaptation to further dosage levels.<\/p><hr data-start=\"2261\" data-end=\"2264\" \/><h2 data-start=\"2266\" data-end=\"2304\">The difference: tirzepatide 2.5 mg vs 5 mg<\/h2><p data-start=\"2306\" data-end=\"2339\">In clinical trial documentation:<\/p><ul data-start=\"2341\" data-end=\"2486\"><li data-start=\"2341\" data-end=\"2401\"><p data-start=\"2343\" data-end=\"2401\"><strong data-start=\"2343\" data-end=\"2365\">tirzepatide 2.5 mg<\/strong> was used as an introductory dose,<\/p><\/li><li data-start=\"2402\" data-end=\"2486\"><p data-start=\"2404\" data-end=\"2486\">Higher doses (5 mg and above) were analyzed for full metabolic effects.<\/p><\/li><\/ul><p data-start=\"2488\" data-end=\"2633\">The evaluation of efficacy in terms of weight reduction was carried out mainly for higher doses under controlled study conditions.<\/p><hr data-start=\"2635\" data-end=\"2638\" \/><h2 data-start=\"2640\" data-end=\"2664\">Qualitative information<\/h2><p data-start=\"2666\" data-end=\"2812\">Offered <strong data-start=\"2676\" data-end=\"2698\">tirzepatide 2.5 mg<\/strong> is subject to qualitative analysis (e.g., HPLC) to confirm purity and compliance with laboratory specifications.<\/p><p data-start=\"2814\" data-end=\"2935\">The product is not a medicinal product or supplement.<br data-start=\"2868\" data-end=\"2871\" \/>Intended for research and analytical applications only.<\/p><hr data-start=\"2937\" data-end=\"2940\" \/><h2 data-start=\"220\" data-end=\"260\">Data from the SURMOUNT-1 clinical trial<\/h2><p data-start=\"262\" data-end=\"420\">In a randomized phase III clinical trial <strong data-start=\"307\" data-end=\"321\">SURMOUNT-1<\/strong> (NEJM, 2022) evaluated the effect of tirzepatide on body weight in obese or overweight individuals without diabetes.<\/p><p data-start=\"422\" data-end=\"572\">The study used a dose escalation scheme beginning with the <strong data-start=\"490\" data-end=\"500\">2.5 mg<\/strong>, and then increased to target levels (5 mg, 10 mg, 15 mg).<\/p><p data-start=\"574\" data-end=\"602\">After 72 weeks of follow-up:<\/p><ul data-start=\"604\" data-end=\"801\"><li data-start=\"604\" data-end=\"674\"><p data-start=\"606\" data-end=\"674\">The average weight reduction was about <strong data-start=\"649\" data-end=\"671\">15% for 5 mg dose<\/strong>,<\/p><\/li><li data-start=\"675\" data-end=\"711\"><p data-start=\"677\" data-end=\"711\">about <strong data-start=\"683\" data-end=\"708\">19.5% for 10 mg dose<\/strong>,<\/p><\/li><li data-start=\"712\" data-end=\"748\"><p data-start=\"714\" data-end=\"748\">about <strong data-start=\"720\" data-end=\"745\">20.9% for 15 mg dose<\/strong>,<\/p><\/li><li data-start=\"749\" data-end=\"801\"><p data-start=\"751\" data-end=\"801\">In the placebo group, the reduction was about <strong data-start=\"792\" data-end=\"800\">3.1%<\/strong>.<\/p><\/li><\/ul><p data-start=\"803\" data-end=\"931\">In addition, improvements in metabolic parameters were observed, including changes in the lipid profile and indices of glucose metabolism.<\/p><p data-start=\"933\" data-end=\"1115\">It is worth noting that <strong data-start=\"954\" data-end=\"1028\">The 2.5 mg dose in clinical trials acted as an introductory dose<\/strong>, used to improve tolerance before reaching higher dosage levels.<\/p><hr data-start=\"2937\" data-end=\"2940\" \/><p data-start=\"2942\" data-end=\"2960\"><a href=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-30655 size-medium\" src=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-300x225.png\" alt=\"Tirzepatide 2.5 mg vial - dual GLP-1\/GIP research peptide, high purity\" width=\"300\" height=\"225\" srcset=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-300x225.png 300w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-400x300.png 400w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-800x600.png 800w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-64x48.png 64w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-768x576.png 768w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera-16x12.png 16w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/2.5mg-0.5ml-Camera.png 1024w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p><p data-start=\"2942\" data-end=\"2960\">Scientific source<\/p><p data-start=\"2962\" data-end=\"3131\">Jastreboff AM et al, <em data-start=\"2984\" data-end=\"3038\">Tirzepatide Once Weekly for the Treatment of Obesity<\/em>, New England Journal of Medicine, 2022.<br data-start=\"3078\" data-end=\"3081\" \/><a class=\"decorated-link\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10088547\/\" target=\"_new\" rel=\"noopener\" data-start=\"3081\" data-end=\"3131\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10088547\/<\/a><\/p><hr data-start=\"2937\" data-end=\"2940\" \/><p data-start=\"2962\" data-end=\"3131\"><strong>Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p><strong data-start=\"116\" data-end=\"138\">Tirzepatide 2.5 mg<\/strong> is a synthetic peptide with dual activity against GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1) receptors. This compound is the subject of research on incretin signaling, regulation of glucose metabolism and mechanisms of energy balance control.<\/p>","protected":false},"featured_media":30655,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"product_brand":[],"product_cat":[15,124,111],"product_tag":[136],"class_list":{"0":"post-13028","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-laboratory-research","7":"product_cat-produkty-w-fiolce","8":"product_cat-glp1gip","9":"product_tag-fiolka","11":"first","12":"instock","13":"shipping-taxable","14":"purchasable","15":"product-type-variable"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/13028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/comments?post=13028"}],"version-history":[{"count":14,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/13028\/revisions"}],"predecessor-version":[{"id":35111,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/13028\/revisions\/35111"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media\/30655"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media?parent=13028"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_brand?post=13028"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_cat?post=13028"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_tag?post=13028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}